Navigation Links
Injection in Medical Technology

FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation

WOODCLIFF LAKE, N.J., Dec. 14 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has approved LUSEDRA(TM) (fospropofol disodium) Injection, an intravenous sedative-hypnotic agent for monitored anesthesia care (MAC) sedation in adult ...

Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma

SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The Takeda Oncology Company today reported updated results based on extended follow up of patients from the large, international Phase III VISTA(1) trial showing continued survival improvement for patients with previously untreated multiple myeloma...

Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients

SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The Takeda Oncology Company today reported updated results from two large, multi-center, randomized Phase III clinical trials of VELCADE based combinations for the induction treatment of transplant-eligible patients with previously untreated multip...

Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients

SAN FRANCISCO, Dec. 7 /PRNewswire/ -- Millennium: The Takeda Oncology Company today reported the Phase I results from a randomized, multi-center, Company-sponsored Phase I/II study of VELCADE, dexamethasone, cyclophosphamide and lenalidomide (VcDCR) in patients with previously untreated multiple m...

Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology

ROCKVILLE, Md., Oct. 14 /PRNewswire-FirstCall/ -- Neuralstem Inc., (Amex: CUR ) today announced that it has licensed the rights to three inventions from Cleveland Clinic pertaining to Targeted Spinal Cord Therapeutics Delivery. All three inventions were developed by Dr. Nicholas Boulis MD, fo...

Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months

BARCELONA, Spain, Sept. 2 /PRNewswire-FirstCall/ -- Final results from a 24-week study presented today at a major medical meeting in Barcelona suggest that investigational olanzapine long-acting injection (LAI) therapeutic doses showed a maintenance of treatment benefit for up to six months. A...

New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients

- Patients in the VELCADE, melphalan and prednisone arm demonstrated a significant survival benefit as well as a 30 percent complete response - CAMBRIDGE, Mass., Aug. 27 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced the publication of results from the 682 patient, ...

BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union

BRIDION allows anesthesiologists to rapidly reverse both moderate and deep levels of muscle relaxation First product approval from the Schering-Plough combination with Organon BioSciences KENILWORTH, N.J., July 29 /PRNewswire-FirstCall/ -- Sch...

Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference

Efficacy and safety data were generally consistent with oral olanzapine with the exception of injection-related events VENICE, Italy, June 23 /PRNewswire-FirstCall/ -- Results from olanzapine long-acting injection (LAI) clinical trials showed that the efficacy and safety profile of...

New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study

Results Presented at the ADA's Annual Scientific Sessions SAN FRANCISCO, June 7 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the results of the dose-finding study for its new injectable diabetes compound AVE0010, a GLP-1 agonist, were presented at the American Diabetes ...

Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss

Submitted to FDA for Stand-Alone Therapy in Q1 2008 SAN FRANCISCO, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli Lilly and Company (NYSE: LLY ) today announced additional results from a study of patients with type 2 diabetes who were unable t...

Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma

CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced the presentation of results from three clinical trials of VELCADE based therapies that showed consistently high complete remission(1) (CR) rates in patients with newly diagnosed multiple my...

VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma

-- IFM presents updated results from Phase III clinical trial -- CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced the presentation of updated results from a 482 patient, multi-center, randomized Phase III clinical trial, comparing VEL...

New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma

- Five Oral Presentations at ASCO Annual Meeting Will Further Demonstrate the Strength of VELCADE Combinations in Front-line Multiple Myeloma - CAMBRIDGE, Mass., May 16 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced that new data from VELCADE clinica...

Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study

Separate Study Showed Significantly Improved Functioning Within Three Months WASHINGTON, May 6 /PRNewswire-FirstCall/ -- Nearly half of patients with schizophrenia fail to remain on their medication treatment, which can result in a relapse of symptoms (1,2). To...

CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model

Data Presented at annual American College of Cardiology (ACC) Scientific Sessions Demonstrates Further Potential of Company's Platform ECM(TM) Technology CHICAGO and ATLANTA, April 1, 2008 /PRNewswire/ -- CorMatrix Cardiovascular, Inc., an Atlanta-based company...

Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm

DEERFIELD, Ill. and VANCOUVER, British Columbia, March 25 /PRNewswire-FirstCall/ -- Astellas Pharma US, Inc. and its co-development partner Cardiome Pharma Corp. (Nasdaq: CRME ; TSX: COM) announced the first pivotal Phase III study evaluating the investigational agent KYNAPID(TM) (vernakalant...

Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma

- Building on Phase III registration trial of VELCADE and rituximab, Millennium initiates new clinical trial with novel combination of VELCADE with bendamustine and rituximab to further advance treatment of patients with follicular lymphoma - CAMBRIDGE, Mass., Feb. 2...

FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment

INDIANAPOLIS, Feb. 6 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration's (FDA) Psychopharmacologic Drugs Advisory Committee voted that, with appropriate labeling around excessive sedation events, Zyprexa(R) long-acting injection (olanzapine LAI) has been shown to be effective and...

New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma

- Three large, randomized Phase III trials of VELCADE in front-line multiple myeloma to be featured as oral presentations at the American Society of Hematology (ASH) Annual Meeting - CAMBRIDGE, Mass., Nov. 26 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq:...

Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset

DEERFIELD, Ill., Oct. 10 /PRNewswire/ -- Astellas Pharma US, Inc. today announced that the investigational agent vernakalant hydrochloride increased conversion to normal heart rhythm (sinus rhythm, or SR) in patients with atrial fibrillation (AF) treated within 48 hours of the onset of symptom...

Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints

- Millennium on track to file sNDA in first quarter 2008 - CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM ) today announced that the interim analysis results of the large, international Phase III VISTA(1) trial in patients with newly...

Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection

SCOTTSDALE, Ariz., Feb. 10 /PRNewswire/ -- Recent clinical data show that Restylane (R) lasted 18 months in 97% of patients with one repeat injection. Restylane (R) is the only HA filler with an 18-month FDA-approved duration claim. These data were generated in a controlled, randomiz...

Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection

CLINTON, N.J., May 19 /PRNewswire/ -- Ikaria Holdings, Inc., a fully integrated critical care biotherapeutics company, announced today that it has completed dosing of its Phase 1a trial for its drug candidate, IK-1001 (sodium sulfide) for injection. The study was a Phase 1, randomized, singl...

MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study of Aquavan Injection in Patients Undergoing Bronchoscopy

MINNEAPOLIS--(BUSINESS WIRE)--Mar 20, 2007 - MGI PHARMA, INC. (NASDAQ: MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that a randomized, double-blind, multi-center, pivotal phase 3 trial of Aquavan(R) (fospropofol disodium) Injection for sedation of patients ...

Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 11, 2007 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, will present preclinical data for Talvesta(tm) (talotrexin) for Injection at the American Association for Cancer Research 100th Annual Meeti...

Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007

MINNEAPOLIS, May 23, 2007 (BUSINESS WIRE) -- MGI PHARMA, INC. (NASDAQ:MOGN), a biopharmaceutical company focused in oncology and acute care, today announced the presentation of results of a successful pivotal phase 3 trial of Aquavan(R) (fospropofol disodium) Injection in patients undergoing colon...

Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop

-- More than 70 abstracts highlight VELCADE efficacy in broad range of patients and across continuum of care -- CAMBRIDGE, Mass., June 19, 2007 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced that data for VELCADE, the market leading therapy with unsurpassed single-agent...

Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients

-- 100 percent response rate achieved with VELCADE, lenalidomide and dexamethasone KOS, Greece, June 28 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported on the presentation of results from four clinical trials of VELCADE based therapies that showed consist...

Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma

- 100 percent of patients treated with VELCADE, cyclophosphamide, and prednisone alive at one year - KOS, Greece, June 28, 2007 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today reported on the presentation of results from clinical trials of VELCADE based therapies that showed high ...

Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival

- New Data from Phase III Intergroupe Francophone du Myelome (IFM) Trial Presented During IMW - CAMBRIDGE, Mass., July 02, 2007 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today reported that new data were presented on the comparative Phase III clinical trial evaluating a VELCADE ba...

Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection

- Findings Published in Blood Highlight Millennium Leadership in Personalized Medicine and Could Strengthen the Role of VELCADE as Foundation of Therapy in Broad Range of Multiple Myeloma Patients - CAMBRIDGE, Mass., April 17, 2007 /PRNewswire-FirstCall/ -- Findings published in the April 15th iss...

Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection

Study Shows Safety and Pharmacokinetics Similar to IV Doses in Phase 3 CLL Trial BERKELEY HEIGHTS, N.J., June 06, 2007 /PRNewswire-FirstCall/ -- Genta Incorporated announced the publication of preliminary clinical results that show the Company's lead anti-cancer drug, Genasense(R) (oblimersen sodi...

Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases

...oes not hinder normal vision. Currently, drugs for most retinal diseases are delivered either through an I.V. drip (i.e. systemically) or by an injection into the eyeball (i.e. intravitreal), both of which pose risks for the patient. For example, chemotherapy for retinoblastoma, a cancer affectin...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

... than or equal to 5% and occurring at least twice as often as placebo) were injection site reactions, somnolence/sedation, dizziness, akathisia and extrapyramida...common side effects in the treatment of schizophrenia were reactions at the injection site, sleepiness, dizziness, feeling of inner restlessness, and abnormal mu...

British Woman Celebrates a Year of Living Cancer-Free

...tt went through a cancer treatment that changed her life -- and made history to boot. Ms. Scott, 54, was the first person in the world to receive an injection of tumor-activated natural killer (TaNK) cells as a treatment for leukemia. Her doctors at the Royal Free Hospital in London recommended this e...

Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy

...etastases despite various therapies. The vaccine treatment was well-tolerated, with most patients experiencing mild skin irritation and redness at the injection site. "The one-year and projected five-year survival rates of 85% and 54%, respectively, are remarkable for melanoma patients with documented m...

Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis

... showed that dirucotide was generally well tolerated. There were no unexpected safety or tolerability issues. The most common side effect reported was injection site reaction. More details of the MAESTRO-01 study results are expected to be presented at a medical conference later this year. Lilly and Bio...

Injection Reverses Heart-Attack Damage

... on the same cellular pathway, Kuhn found. "We applied periostin locally at the site of cardiac injury, but NRG1 works when given by systemic injection - a very promising result that suggests it may be feasible to use this in the clinic to treat heart failure," says Kuhn, who won a first prize Young I...

Awardees for the 2009 Young Investigator Grant for Probiotics Research Announced

...on to producing the internationally recognized probiotic beverage, Yakult is also accredited in the pharmaceutical field for its development of Campto injection (Camptosar), the first-line drug for colorectal cancer in the U.S. Yakult U.S.A. Inc., the subsidiary of Yakult Honsha Co., Ltd., is stationed in Tor...
Other Tags
(Date:10/22/2014)... 20, 2014  Leading identity analyst firm Acuity Market ... the world,s population will have a chip-based National eID ... . Asia , with its ... for more than 60% of all National eID cards ... -- "The Global National eID Industry Report: ...
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Whole-exome sequencing shows potential as diagnostic tool 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment period starting ... Research (AIR) finds that three out of four Americans are ... percent say they are not likely or only somewhat likely ... , The AIR survey found wide gaps in Americans’ health ... how much they owe for a routine doctor’s visit. , ...
(Date:10/22/2014)... 2014 Although there are only 24 hours in ... people who have trouble finding time within their busy schedules for ... long periods of time to get in shape. Here are five ... the go. , Change Up Your Commute , Consider riding ... add some exercise into your daily routine. If you must use ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter , ... in vitro fertilization (IVF) are only about half as likely ... reproduction technique, new research indicates, and the racial disparity persists ... about 31 percent of white patients became pregnant after IVF, ... more than 4,000 IVF cycles over two years to tease ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... health officials on Monday officially tightened guidelines for health workers ... skin exposure and use of a respirator at all times. ... to issue the tougher rules after two Dallas nurses contracted ... the United States, Liberian national Thomas Eric Duncan. Nina Pham ...
(Date:10/20/2014)... The Advocator Group, LLC is proud ... for Suicide Prevention’s (AFSP) Out of the Darkness walk ... that hosts hundreds of community walks throughout the country ... to help understand and prevent suicide through not only ... , The Advocator Group shares this passion for ...
Breaking Medicine News(10 mins):Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3
Other Contents